HengJia Neoantigen Biotechnology

HengJia Neoantigen Biotechnology is a clinical-stage biotechnology company based in Shenzhen, China, specializing in personalized cancer immunotherapy. The company leverages a proprietary bioinformatics and artificial intelligence platform to identify and predict tumor-specific neoantigens for individual patients. Its primary product candidates include personalized neoantigen peptide vaccines and neoantigen-targeted T-cell therapies aimed at treating various solid tumors, such as liver and lung cancers. HengJia focuses on the integration of high-throughput sequencing, immune monitoring, and advanced algorithms to develop precision medicine solutions. The company has established collaborations with major clinical centers in China to validate its technology in investigator-initiated clinical trials.